Letrozole normalizes serum testosterone in severely obese men with hypogonadotropic hypogonadism
Background: Morbid obesity is associated with increased estradiol production as a result of aromatase‐dependent conversion of testosterone to estradiol. The elevated serum estradiol levels may inhibit pituitary LH secretion to such extent that hypogonadotropic hypogonadism can result. Normalization...
Gespeichert in:
| Veröffentlicht in: | Diabetes, obesity & metabolism obesity & metabolism, 2005-05, Vol.7 (3), p.211-215 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 215 |
|---|---|
| container_issue | 3 |
| container_start_page | 211 |
| container_title | Diabetes, obesity & metabolism |
| container_volume | 7 |
| creator | De Boer, H. Verschoor, L. Ruinemans-Koerts, J. Jansen, M. |
| description | Background: Morbid obesity is associated with increased estradiol production as a result of aromatase‐dependent conversion of testosterone to estradiol. The elevated serum estradiol levels may inhibit pituitary LH secretion to such extent that hypogonadotropic hypogonadism can result. Normalization of the disturbed estradiol‐testosterone balance may be beneficial to reverse the adverse effects of hypogonadism.
Aim: To examine whether aromatase inhibition with Letrozole can normalize serum testosterone levels in severely obese men with hypogonadotropic hypogonadism.
Patients and Methods: Ten severely obese men, mean age 48.2 ± 2.3 (s.e.) years and body mass index 42.1 ± 2.6 kg/m2, were treated with Letrozole for 6 weeks in doses ranging from 7.5 to 17.5 mg per week.
Results: Six weeks of treatment decreased serum estradiol from 120 ± 20 to 70 ± 9 pmol/l (p = 0.006). None of the subjects developed an estradiol level of less than 40 pmol/l. LH increased from 4.5 ± 0.8 to 14.8 ± 2.3 U/l (p |
| doi_str_mv | 10.1111/j.1463-1326.2004.00397.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67712350</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>67712350</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4047-8a13b5bddd526aba6fda1d77734aefae19131e25b8f2ef0e5b334f6ec9bb74dc3</originalsourceid><addsrcrecordid>eNqNkMtOwzAQRS0EouXxC8grdgl2nMSpxAa1FJBaYMFjaexkQl2SuNgptP16XFqVLbOZ0fje69FBCFMSUl8X05DGKQsoi9IwIiQOCWE9Hi72UHf3sP87R0HWI1EHHTk3JV7JMn6IOjTJfAxLu-htBK01K1MBboytZaVX4LADO69xC641rgVrGsC68dsvsFAtsVHgANfQ4G_dTvBkOTPvppGF8VEznf8ttKtP0EEpKwen236MnofXT_3bYPRwc9e_GgV5TGIeZJIylaiiKJIolUqmZSFpwTlnsYRSAu1RRiFKVFZGUBJIFGNxmULeU4rHRc6O0fkmd2bN59xfLmrtcqgq2YCZO5FyTiOWEC_MNsLcGucslGJmdS3tUlAi1nTFVKwhijVEsaYrfumKhbeebf-YqxqKP-MWpxdcbgTfuoLlv4PF4GHsB28PNnbtqS92dmk__PmMJ-L1_kYMX57Gw8EjESP2A2f5m2s</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>67712350</pqid></control><display><type>article</type><title>Letrozole normalizes serum testosterone in severely obese men with hypogonadotropic hypogonadism</title><source>Wiley Online Library - AutoHoldings Journals</source><source>MEDLINE</source><creator>De Boer, H. ; Verschoor, L. ; Ruinemans-Koerts, J. ; Jansen, M.</creator><creatorcontrib>De Boer, H. ; Verschoor, L. ; Ruinemans-Koerts, J. ; Jansen, M.</creatorcontrib><description>Background: Morbid obesity is associated with increased estradiol production as a result of aromatase‐dependent conversion of testosterone to estradiol. The elevated serum estradiol levels may inhibit pituitary LH secretion to such extent that hypogonadotropic hypogonadism can result. Normalization of the disturbed estradiol‐testosterone balance may be beneficial to reverse the adverse effects of hypogonadism.
Aim: To examine whether aromatase inhibition with Letrozole can normalize serum testosterone levels in severely obese men with hypogonadotropic hypogonadism.
Patients and Methods: Ten severely obese men, mean age 48.2 ± 2.3 (s.e.) years and body mass index 42.1 ± 2.6 kg/m2, were treated with Letrozole for 6 weeks in doses ranging from 7.5 to 17.5 mg per week.
Results: Six weeks of treatment decreased serum estradiol from 120 ± 20 to 70 ± 9 pmol/l (p = 0.006). None of the subjects developed an estradiol level of less than 40 pmol/l. LH increased from 4.5 ± 0.8 to 14.8 ± 2.3 U/l (p < 0.001). Total testosterone rose from 7.5 ± 1.0 to 23.8 ± 3.0 nmol/l (p < 0.001) without a concomitant change in sex hormone‐binding globulin level. Those treated with Letrozole 17.5 mg per week had an excessive LH response.
Conclusion: Short‐term Letrozole treatment normalized serum testosterone levels in all obese men. The clinical significance of this intervention remains to be established in controlled, long‐term studies.</description><identifier>ISSN: 1462-8902</identifier><identifier>EISSN: 1463-1326</identifier><identifier>DOI: 10.1111/j.1463-1326.2004.00397.x</identifier><identifier>PMID: 15811136</identifier><language>eng</language><publisher>Oxford, UK; Malden, USA: Blackwell Science Ltd</publisher><subject>aromatase inhibition ; Aromatase Inhibitors - therapeutic use ; Dose-Response Relationship, Drug ; Drug Administration Schedule ; Estradiol - blood ; Gonadotropins, Pituitary - blood ; Humans ; Hypogonadism - blood ; Hypogonadism - drug therapy ; Male ; male hypogonadism ; Middle Aged ; Nitriles - therapeutic use ; obesity ; Obesity, Morbid - blood ; Obesity, Morbid - drug therapy ; Pilot Projects ; Sex Hormone-Binding Globulin - analysis ; Testosterone - blood ; Triazoles - therapeutic use</subject><ispartof>Diabetes, obesity & metabolism, 2005-05, Vol.7 (3), p.211-215</ispartof><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4047-8a13b5bddd526aba6fda1d77734aefae19131e25b8f2ef0e5b334f6ec9bb74dc3</citedby><cites>FETCH-LOGICAL-c4047-8a13b5bddd526aba6fda1d77734aefae19131e25b8f2ef0e5b334f6ec9bb74dc3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1463-1326.2004.00397.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1463-1326.2004.00397.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15811136$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>De Boer, H.</creatorcontrib><creatorcontrib>Verschoor, L.</creatorcontrib><creatorcontrib>Ruinemans-Koerts, J.</creatorcontrib><creatorcontrib>Jansen, M.</creatorcontrib><title>Letrozole normalizes serum testosterone in severely obese men with hypogonadotropic hypogonadism</title><title>Diabetes, obesity & metabolism</title><addtitle>Diabetes Obes Metab</addtitle><description>Background: Morbid obesity is associated with increased estradiol production as a result of aromatase‐dependent conversion of testosterone to estradiol. The elevated serum estradiol levels may inhibit pituitary LH secretion to such extent that hypogonadotropic hypogonadism can result. Normalization of the disturbed estradiol‐testosterone balance may be beneficial to reverse the adverse effects of hypogonadism.
Aim: To examine whether aromatase inhibition with Letrozole can normalize serum testosterone levels in severely obese men with hypogonadotropic hypogonadism.
Patients and Methods: Ten severely obese men, mean age 48.2 ± 2.3 (s.e.) years and body mass index 42.1 ± 2.6 kg/m2, were treated with Letrozole for 6 weeks in doses ranging from 7.5 to 17.5 mg per week.
Results: Six weeks of treatment decreased serum estradiol from 120 ± 20 to 70 ± 9 pmol/l (p = 0.006). None of the subjects developed an estradiol level of less than 40 pmol/l. LH increased from 4.5 ± 0.8 to 14.8 ± 2.3 U/l (p < 0.001). Total testosterone rose from 7.5 ± 1.0 to 23.8 ± 3.0 nmol/l (p < 0.001) without a concomitant change in sex hormone‐binding globulin level. Those treated with Letrozole 17.5 mg per week had an excessive LH response.
Conclusion: Short‐term Letrozole treatment normalized serum testosterone levels in all obese men. The clinical significance of this intervention remains to be established in controlled, long‐term studies.</description><subject>aromatase inhibition</subject><subject>Aromatase Inhibitors - therapeutic use</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drug Administration Schedule</subject><subject>Estradiol - blood</subject><subject>Gonadotropins, Pituitary - blood</subject><subject>Humans</subject><subject>Hypogonadism - blood</subject><subject>Hypogonadism - drug therapy</subject><subject>Male</subject><subject>male hypogonadism</subject><subject>Middle Aged</subject><subject>Nitriles - therapeutic use</subject><subject>obesity</subject><subject>Obesity, Morbid - blood</subject><subject>Obesity, Morbid - drug therapy</subject><subject>Pilot Projects</subject><subject>Sex Hormone-Binding Globulin - analysis</subject><subject>Testosterone - blood</subject><subject>Triazoles - therapeutic use</subject><issn>1462-8902</issn><issn>1463-1326</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkMtOwzAQRS0EouXxC8grdgl2nMSpxAa1FJBaYMFjaexkQl2SuNgptP16XFqVLbOZ0fje69FBCFMSUl8X05DGKQsoi9IwIiQOCWE9Hi72UHf3sP87R0HWI1EHHTk3JV7JMn6IOjTJfAxLu-htBK01K1MBboytZaVX4LADO69xC641rgVrGsC68dsvsFAtsVHgANfQ4G_dTvBkOTPvppGF8VEznf8ttKtP0EEpKwen236MnofXT_3bYPRwc9e_GgV5TGIeZJIylaiiKJIolUqmZSFpwTlnsYRSAu1RRiFKVFZGUBJIFGNxmULeU4rHRc6O0fkmd2bN59xfLmrtcqgq2YCZO5FyTiOWEC_MNsLcGucslGJmdS3tUlAi1nTFVKwhijVEsaYrfumKhbeebf-YqxqKP-MWpxdcbgTfuoLlv4PF4GHsB28PNnbtqS92dmk__PmMJ-L1_kYMX57Gw8EjESP2A2f5m2s</recordid><startdate>200505</startdate><enddate>200505</enddate><creator>De Boer, H.</creator><creator>Verschoor, L.</creator><creator>Ruinemans-Koerts, J.</creator><creator>Jansen, M.</creator><general>Blackwell Science Ltd</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200505</creationdate><title>Letrozole normalizes serum testosterone in severely obese men with hypogonadotropic hypogonadism</title><author>De Boer, H. ; Verschoor, L. ; Ruinemans-Koerts, J. ; Jansen, M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4047-8a13b5bddd526aba6fda1d77734aefae19131e25b8f2ef0e5b334f6ec9bb74dc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>aromatase inhibition</topic><topic>Aromatase Inhibitors - therapeutic use</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drug Administration Schedule</topic><topic>Estradiol - blood</topic><topic>Gonadotropins, Pituitary - blood</topic><topic>Humans</topic><topic>Hypogonadism - blood</topic><topic>Hypogonadism - drug therapy</topic><topic>Male</topic><topic>male hypogonadism</topic><topic>Middle Aged</topic><topic>Nitriles - therapeutic use</topic><topic>obesity</topic><topic>Obesity, Morbid - blood</topic><topic>Obesity, Morbid - drug therapy</topic><topic>Pilot Projects</topic><topic>Sex Hormone-Binding Globulin - analysis</topic><topic>Testosterone - blood</topic><topic>Triazoles - therapeutic use</topic><toplevel>online_resources</toplevel><creatorcontrib>De Boer, H.</creatorcontrib><creatorcontrib>Verschoor, L.</creatorcontrib><creatorcontrib>Ruinemans-Koerts, J.</creatorcontrib><creatorcontrib>Jansen, M.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Diabetes, obesity & metabolism</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>De Boer, H.</au><au>Verschoor, L.</au><au>Ruinemans-Koerts, J.</au><au>Jansen, M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Letrozole normalizes serum testosterone in severely obese men with hypogonadotropic hypogonadism</atitle><jtitle>Diabetes, obesity & metabolism</jtitle><addtitle>Diabetes Obes Metab</addtitle><date>2005-05</date><risdate>2005</risdate><volume>7</volume><issue>3</issue><spage>211</spage><epage>215</epage><pages>211-215</pages><issn>1462-8902</issn><eissn>1463-1326</eissn><abstract>Background: Morbid obesity is associated with increased estradiol production as a result of aromatase‐dependent conversion of testosterone to estradiol. The elevated serum estradiol levels may inhibit pituitary LH secretion to such extent that hypogonadotropic hypogonadism can result. Normalization of the disturbed estradiol‐testosterone balance may be beneficial to reverse the adverse effects of hypogonadism.
Aim: To examine whether aromatase inhibition with Letrozole can normalize serum testosterone levels in severely obese men with hypogonadotropic hypogonadism.
Patients and Methods: Ten severely obese men, mean age 48.2 ± 2.3 (s.e.) years and body mass index 42.1 ± 2.6 kg/m2, were treated with Letrozole for 6 weeks in doses ranging from 7.5 to 17.5 mg per week.
Results: Six weeks of treatment decreased serum estradiol from 120 ± 20 to 70 ± 9 pmol/l (p = 0.006). None of the subjects developed an estradiol level of less than 40 pmol/l. LH increased from 4.5 ± 0.8 to 14.8 ± 2.3 U/l (p < 0.001). Total testosterone rose from 7.5 ± 1.0 to 23.8 ± 3.0 nmol/l (p < 0.001) without a concomitant change in sex hormone‐binding globulin level. Those treated with Letrozole 17.5 mg per week had an excessive LH response.
Conclusion: Short‐term Letrozole treatment normalized serum testosterone levels in all obese men. The clinical significance of this intervention remains to be established in controlled, long‐term studies.</abstract><cop>Oxford, UK; Malden, USA</cop><pub>Blackwell Science Ltd</pub><pmid>15811136</pmid><doi>10.1111/j.1463-1326.2004.00397.x</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1462-8902 |
| ispartof | Diabetes, obesity & metabolism, 2005-05, Vol.7 (3), p.211-215 |
| issn | 1462-8902 1463-1326 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67712350 |
| source | Wiley Online Library - AutoHoldings Journals; MEDLINE |
| subjects | aromatase inhibition Aromatase Inhibitors - therapeutic use Dose-Response Relationship, Drug Drug Administration Schedule Estradiol - blood Gonadotropins, Pituitary - blood Humans Hypogonadism - blood Hypogonadism - drug therapy Male male hypogonadism Middle Aged Nitriles - therapeutic use obesity Obesity, Morbid - blood Obesity, Morbid - drug therapy Pilot Projects Sex Hormone-Binding Globulin - analysis Testosterone - blood Triazoles - therapeutic use |
| title | Letrozole normalizes serum testosterone in severely obese men with hypogonadotropic hypogonadism |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T02%3A53%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Letrozole%20normalizes%20serum%20testosterone%20in%20severely%20obese%20men%20with%20hypogonadotropic%20hypogonadism&rft.jtitle=Diabetes,%20obesity%20&%20metabolism&rft.au=De%20Boer,%20H.&rft.date=2005-05&rft.volume=7&rft.issue=3&rft.spage=211&rft.epage=215&rft.pages=211-215&rft.issn=1462-8902&rft.eissn=1463-1326&rft_id=info:doi/10.1111/j.1463-1326.2004.00397.x&rft_dat=%3Cproquest_cross%3E67712350%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=67712350&rft_id=info:pmid/15811136&rfr_iscdi=true |